Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board

Fresenius Medical Care (NYSE:FMS) appointed Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board, effective Jan 1, 2026.

Rhea-AI Summary

Fresenius Medical Care (NYSE:FMS) appointed Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board, effective Jan 1, 2026. He succeeds Franklin W. Maddux, who will retire at year-end as part of a planned transition.

Hugh-Jones joins from Volastra Therapeutics after leadership roles at Allergan, Pfizer and Sanofi. The company highlighted the 5008X CAREsystem rollout in the U.S. and noted its network serves ~294,000 patients across 3,628 clinics worldwide.

Positive

• Management Board strengthened by experienced medical leader
• Direct successor named with Jan 1, 2026 effective date
• Company highlights U.S. 5008X CAREsystem rollout
• Global footprint: 294,000 patients in 3,628 clinics

Negative

• Planned retirement creates leadership transition risks into 2026

Argus Dec 10 session

+3.04% close to close Open Argus

Details

News Market Reaction – FMS

On Dec 10, the day this news came out, FMS closed 3.04% above the previous close.

Data tracked by StockTitan Argus for the Dec 10 session.

Key Figures

Effective date: January 1, 2026 Age of Charles Hugh-Jones: 56 years Age of Franklin W. Maddux: 68 years +3 more

Effective date

January 1, 2026

Start of Charles Hugh-Jones’ role as Global Chief Medical Officer

Age of Charles Hugh-Jones

56 years

Stated age of incoming Global Chief Medical Officer

Age of Franklin W. Maddux

68 years

Stated age of retiring Global Chief Medical Officer

Global dialysis patients

4.2 million patients

Worldwide patients regularly undergoing dialysis treatment

Dialysis clinics network

3,628 clinics

Company’s global network of dialysis clinics in article

Patients treated

294,000 patients

Patients treated through Fresenius Medical Care clinics

Historical Context

5 past events · Latest: Nov 04

5 events

1. Nov 04

   Q3 2025 earnings

   24h Move

   -7.8%

   Strong revenue and operating income growth with buyback progress reported.

2. Oct 30

   Conference research

   24h Move

   -0.8%

   New real-world data on hemodiafiltration and AI tools at ASN Kidney Week.

3. Oct 01

   Management change

   24h Move

   +1.1%

   Appointment of Joseph E. Turk to the Management Board for Care Enablement.

4. Sep 18

   Strategy & VBC update

   24h Move

   -0.4%

   EUR 312m Interwell Health ownership increase and new VBC segment leader.

5. Aug 11

   Share buyback

   24h Move

   +0.2%

   Announcement of first tranche of up to EUR 600m in a EUR 1bn buyback.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

renal diseases, dialysis, dialyzers, forward-looking statements

4 terms

renal diseases medical

"provider of products and services for individuals with renal diseases of which around"

Renal diseases are conditions that damage the kidneys’ ability to filter waste, balance fluids, and regulate blood pressure, ranging from mild impairment to kidney failure that may require dialysis or transplant. For investors, these diseases drive demand for diagnostics, medicines, medical devices, and long-term care—think of kidneys as a home’s plumbing: when they fail, products and treatments to repair or replace that system become commercially important and can affect company revenues and regulatory scrutiny.

dialysis medical

"4.2 million patients worldwide regularly undergo dialysis treatment."

Dialysis is a medical treatment that cleans the blood and removes extra fluid when the kidneys can no longer do that job, using a machine or a filtered solution much like an external water filter for the body. It matters to investors because dialysis creates steady demand for specialized clinics, machines, supplies and drugs, driving predictable revenue streams, capital and regulatory risks, and long-term patient volumes that affect healthcare company valuations.

dialyzers medical

"leading provider of dialysis products such as dialysis machines or dialyzers."

Dialyzers are medical devices that act like an artificial kidney, filtering waste and excess fluid from the blood for patients with kidney failure. Think of them as a specialized water filter for the bloodstream; they are consumable components used each dialysis session and thus drive recurring revenue, supply chain needs, and regulatory scrutiny—factors that can directly affect healthcare companies’ sales, margins, and investor risk.

forward-looking statements regulatory

"This release contains forward-looking statements that are subject to various risks"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Effective January 1, 2026, Charles Hugh-Jones will join the Management Board as Global Chief Medical Officer
• As part of a planned transition Franklin W. Maddux will retire by year end

BAD HOMBURG, Germany, Dec. 10, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, has appointed Charles Hugh-Jones, MD, FRCP (56) as a member of the Management Board, effective January 1, 2026. Mr. Hugh-Jones will serve as Global Chief Medical Officer.

Mr. Hugh-Jones will succeed Franklin (Frank) W. Maddux, MD (68) as part of a planned transition after Mr. Maddux informed the Supervisory Board of his intention to retire.

Mr. Hugh-Jones most recently served as CEO of Volastra Therapeutics from its inception as a discovery-stage startup to a clinical-stage biotech company, advancing novel oncology assets. Prior to Volastra, he served as Chief Medical Officer at Allergan – later acquired by AbbVie –, overseeing global medical operations and leading major product launches across multiple therapeutic areas. He also held senior leadership roles at Pfizer and Sanofi, driving innovation in chronic disease care, diabetes, cardiovascular and other therapeutic areas. Mr. Hugh-Jones holds an MD from Charing Cross and Westminster Medical School, University of London, and is a Fellow of the Royal College of Physicians of the UK.

Michael Sen, Chairman of the Supervisory Board, commented: "We welcome Charles Hugh-Jones to the Management Board of Fresenius Medical Care. His expertise, experience and recognition as a leader in the medical area will be key to fostering Fresenius Medical Care´s leadership position in the renal area. We are delighted that we found such a capable successor." Michael Sen added: "On behalf of the entire Supervisory Board, I would like to express my sincere appreciation to Frank for his excellent work and commitment over the past years. We wish him all the best for his retirement."

Helen Giza, CEO and Chair of the Management Board, said: "The Management Board is further strengthened by Charles' broad corporate experience and clinical leadership. He brings a fresh vantage point that reinforces our strength in renal care while pushing us to think wider and more creatively about the future of patient care. I would like to thank Frank for his dedication and contributions, which have left a lasting impact on our company. We wish him a very happy retirement and sincerely thank him for his outstanding service."

Charles Hugh-Jones said: "I am excited to join Fresenius Medical Care at a time when the company is about to set a new standard of kidney care in the U.S. with the rollout of the 5008X CAREsystem and continues to lead kidney care worldwide. The Global Medical Office will play an important role in advancing kidney care for patients and their families."

About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,628 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 294,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company's website at www.freseniusmedicalcare.com.

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

Media contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com

Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com

www.freseniusmedicalcare.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-appoints-charles-hugh-jones-as-global-chief-medical-officer-and-member-of-the-management-board-302637882.html

SOURCE Fresenius Medical Care Holdings, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is Charles Hugh-Jones and when does he start as Global Chief Medical Officer of FMS?

Charles Hugh-Jones, MD, FRCP, will join as Global Chief Medical Officer and Management Board member effective January 1, 2026.

Who will Charles Hugh-Jones succeed at Fresenius Medical Care (FMS)?

He will succeed Franklin (Frank) W. Maddux, MD, who will retire at year-end as part of a planned transition.

What relevant experience does the new FMS Global Chief Medical Officer have?

Hugh-Jones led Volastra Therapeutics as CEO and held senior medical roles at Allergan, Pfizer and Sanofi.

How large is Fresenius Medical Care's patient and clinic network mentioned in the announcement?

The company serves approximately 294,000 patients across 3,628 dialysis clinics worldwide.

What product rollout did Fresenius Medical Care highlight alongside the leadership change?

The company referenced the U.S. rollout of the 5008X CAREsystem as a near-term focus.